| Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial E Versteijne, JL van Dam, M Suker, QP Janssen, K Groothuis, ... Journal of Clinical Oncology 40 (11), 1220-1230, 2022 | 364 | 2022 |
| International validation of the eighth edition of the American Joint Committee on Cancer (AJCC) TNM staging system in patients with resected pancreatic cancer S Van Roessel, GG Kasumova, J Verheij, RM Najarian, L Maggino, ... JAMA surgery 153 (12), e183617-e183617, 2018 | 249 | 2018 |
| Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer … QP Janssen, JL van Dam, BA Bonsing, H Bos, KP Bosscha, P Coene, ... BMC cancer 21, 1-8, 2021 | 118 | 2021 |
| Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials JL van Dam, QP Janssen, MG Besselink, MYV Homs, HC van Santvoort, ... European Journal of Cancer 160, 140-149, 2022 | 113 | 2022 |
| Outcomes of a multicenter training program in robotic pancreatoduodenectomy (LAELAPS-3) MJW Zwart, CLM Nota, T De Rooij, J Van Hilst, WW Te Riele, ... Annals of surgery 276 (6), e886-e895, 2022 | 79 | 2022 |
| Robotic distal pancreatectomy: a novel standard of care? benchmark values for surgical outcomes from 16 international expert centers PC Müller, E Breuer, F Nickel, S Zani Jr, E Kauffmann, L De Franco, ... Annals of surgery 278 (2), 253-259, 2023 | 39 | 2023 |
| Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: a multicentre retrospective cohort study S van Roessel, EC Soer, LA Daamen, D van Dalen, AF Sarasqueta, ... European Journal of Surgical Oncology 47 (10), 2525-2532, 2021 | 29 | 2021 |
| Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis QP Janssen, JL van Dam, IG Kivits, MG Besselink, CHJ van Eijck, ... Annals of surgical oncology 28 (13), 8297-8308, 2021 | 24 | 2021 |
| Impact of borderline resectability in pancreatic head cancer on patient survival: biology matters according to the new international consensus criteria F Anger, A Döring, J van Dam, JF Lock, I Klein, M Bittrich, CT Germer, ... Annals of surgical oncology 28, 2325-2336, 2021 | 23 | 2021 |
| FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium QP Janssen, JL Van Dam, D Doppenberg, LR Prakash, CHJ Van Eijck, ... JNCI: Journal of the National Cancer Institute 114 (5), 695-703, 2022 | 21 | 2022 |
| The prognosis of kidney transplant recipients with aorto‐iliac calcification: a systematic review and meta‐analysis E Rijkse, JL van Dam, JI Roodnat, HJAN Kimenai, JNM IJzermans, ... Transplant International 33 (5), 483-496, 2020 | 19 | 2020 |
| Neoadjuvant radiotherapy after (m) FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: A TAPS Consortium study QP Janssen, JL van Dam, LR Prakash, D Doppenberg, CH Crane, ... Journal of the National Comprehensive Cancer Network 20 (7), 783-791. e1, 2022 | 15 | 2022 |
| Impact of aortoiliac stenosis on graft and patient survival in kidney transplant recipients using the TASC II classification E Rijkse, HJAN Kimenai, JI Roodnat, S Ten Raa, DC Bijdevaate, ... Transplantation 103 (10), 2164-2172, 2019 | 12 | 2019 |
| The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program:“Standing on the Shoulders of Giants” MJW Zwart, B Van Den Broek, N De Graaf, JA Suurmeijer, S Augustinus, ... Annals of surgery 278 (6), e1232-e1241, 2023 | 8 | 2023 |
| Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial JL van Dam, EMM Verkolf, EN Dekker, BA Bonsing, SO Bratlie, ... BMC cancer 23 (1), 728, 2023 | 8 | 2023 |
| Treatment response and conditional survival in advanced pancreatic cancer patients treated with FOLFIRINOX: a multicenter cohort study F van der Sijde, JL van Dam, B Groot Koerkamp, B Haberkorn, ... Journal of oncology 2022, 2022 | 7 | 2022 |
| LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A … BG Koerkamp, QP Janssen, JL van Dam, BA Bonsing, H Bos, KP Bosscha, ... Annals of Oncology 34, S1323, 2023 | 6 | 2023 |
| Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma A Belkouz, S Van Roessel, M Strijker, JL van Dam, L Daamen, ... British journal of cancer 126 (9), 1280-1288, 2022 | 6 | 2022 |
| Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence–Based Model D Bertsimas, GA Margonis, Y Huang, N Andreatos, H Wiberg, Y Ma, ... JCO Clinical Cancer Informatics 5, 1220-1231, 2021 | 6 | 2021 |
| International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. JAMA Surg. 2018 … S van Roessel, GG Kasumova, J Verheij, RM Najarian, L Maggino, ... | 6 | 2018 |
